Skip to main content

Ultrasound method restores dopaminergic pathway in brain at Parkinson's early stages

While there are several thousand drugs available to treat a wide range of brain diseases, from depression to schizophrenia, they cannot penetrate the blood-brain barrier (BBB) into the brain. The BBB, which protects the brain from pathogens that may be present in blood, also prevents most drugs from gaining access to the brain functional tissue, the parenchyma, a well-known challenge to the treatment of all brain diseases including neurodegenerative disorders like Parkinson's disease and Alzheimer's.
A team led by Elisa Konofagou, Robert and Margaret Hariri Professor of Biomedical Engineering and Professor of Radiology (Physics) at Columbia Engineering, has been developing a novel technique that could open up new ways to facilitate targeted drug delivery into the brain and enable drugs to treat brain diseases more focally. The researchers used transcranial, focused ultrasound and intravenously injected microbubbles into the BBB to make a localized and transient opening that allows drugs to cross through the BBB reversibly and non-invasively. Focusing on Parkinson's disease, in collaboration with Serge Przedborski's group in the department of neurology at Columbia University Irving Medical Center, they discovered that protein delivery and gene delivery across the BBB can partly restore the dopaminergic pathways, the neurons in the brain that are affected in early Parkinson's disease.
"We found both behavioral and anatomical neuronal improvements in the brain," says Konofagou, who led the study, published online on April 4 by the Journal of Controlled Release, and in print June 10. "This is the first time that anyone has been able to restore a dopaminergic pathway with available drugs at the early stages of Parkinson's disease. We were able to curb the rapid progression of neurodegeneration while improving the neuronal function. We expect our study will open new therapeutic avenues for the early treatment of central nervous system diseases."
The team targeted the brain regions involved in early stage Parkinson's and Alzheimer's disease, such as the putamen and hippocampus. The tool they developed for the study is a device that uses a neuronavigation system to direct the treatment in real-time. The U.S. FDA has just assigned the team an Investigational Device Exemption (IDE) to use the device in clinical trials to test its safety in Alzheimer's patients.
"Neurosurgeons use such systems all the time to guide them for neurosurgery," says Antonios Pouliopoulos, associate research scientist in Konofagou's lab who worked on the development of the clinical neuronavigation system. "Our group just replaced the surgical instrument with an ultrasound transducer to perform our non-invasive procedure."
Konofagou's Ultrasound Elasticity and Imaging Laboratory is the only academic lab in the U.S. to receive FDA approval for ultrasound-assisted, blood-brain-barrier opening. Other groups doing similar research either use nanoparticles to facilitate drug delivery or require MRI to guide the procedure. Konofagou's approach is MRI-independent and does not require any nanoparticles.
Her device is a single-element transducer that is much smaller, faster, and less expensive than current helmet-shaped, 1024-element transducer systems that use MRI guidance. Because Konofagou's system is portable, doctors will be able to treat patients anywhere in a hospital and, in the future, even at a patient's home. Treatment can be completed in less than 30 minutes, compared to three to four hours for MRI-guided therapy, and monitored in real-time, a unique feature of the new device. The cost is 10 times less than the MRI-guided helmet. The first trial with the device will be with Alzheimer's patients, after which Konofagou plans to work with Parkinson's patients.
Konafagou recently won a four-year $2.5M NIH grant to use a similar device for deep brain stimulation aiming to unveil the mechanism by which ultrasound excites neurons and to monitor the unveiled mechanism in human subjects. In addition, she will be honored with the 2019 Engineering in Medicine and Biology Society's Technical Achievement Award in Berlin this July for her "outstanding and pioneering contributions in the field of ultrasound imaging and therapy, and their application and clinical translation to the diagnosis of cardiovascular diseases, tumor diagnosis and treatment as well as brain drug delivery and stimulation."
"We all have loved ones with neurodegenerative disorders," Konofagou adds. "My grandmother has been suffering from dementia for more than five years, so I know first-hand how essential it would be to have a simple device that can be wheeled into the patient's home and offer a higher quality of life, especially for our rapidly aging population. And there are so many deadly diseases like brain tumors that affect people of all ages, with no cure yet in sight. That's why we want to bring our research so rapidly to the clinic."
Story Source:
Materials provided by Columbia University School of Engineering and Applied Science. Original written by Holly Evarts. 
Note: Content may be edited.

Comments

Post a Comment

Popular posts from this blog

Dark matter may be older than the Big Bang

Dark matter, which researchers believe make up about 80% of the universe's mass, is one of the most elusive mysteries in modern physics. What exactly it is and how it came to be is a mystery, but a new Johns Hopkins University study now suggests that dark matter may have existed before the Big Bang. The study, published August 7 in  Physical Review Letters , presents a new idea of how dark matter was born and how to identify it with astronomical observations. "The study revealed a new connection between particle physics and astronomy. If dark matter consists of new particles that were born before the Big Bang, they affect the way galaxies are distributed in the sky in a unique way. This connection may be used to reveal their identity and make conclusions about the times before the Big Bang too," says Tommi Tenkanen, a postdoctoral fellow in Physics and Astronomy at the Johns Hopkins University and the study's author. While not much is known about its origins,...
Post a Comment
Read more

Home births as safe as hospital births: International study suggests

A large international study led by McMaster University shows that low risk pregnant women who intend to give birth at home have no increased chance of the baby's perinatal or neonatal death compared to other low risk women who intend to give birth in a hospital. The results have been published by  The Lancet 's  EClinicalMedicine  journal. "More women in well-resourced countries are choosing birth at home, but concerns have persisted about their safety," said Eileen Hutton, professor emeritus of obstetrics and gynecology at McMaster, founding director of the McMaster Midwifery Research Centre and first author of the paper. "This research clearly demonstrates the risk is no different when the birth is intended to be at home or in hospital." The study examined the safety of place of birth by reporting on the risk of death at the time of birth or within the first four weeks, and found no clinically important or statistically different risk between home...
Post a Comment
Read more

GSAT-11 satellite to be launched from French Guiana on Dec 5th

GSAT-11 satellite to be launched from French Guiana on Dec 5th GSAT-11 would be located at 74 East and is the fore-runner in a series of advanced communications satellite with multi-spot beam antenna coverage over Indian mainland and Islands, ISRO said. GSAT-11 is the next generation “high throughput” communication satellite configured around ISRO’s I-6K Bus. (PTI/Representational). Indian space agency ISRO is scheduled to launch GSAT-11, the “heaviest” satellite built by it, on-board Ariane-5 rocket of Arianespace from French Guiana on December 5. Weighing about 5,854 kg, GSAT-11 would play a vital role in providing broadband services across the country, and also provide a platform to demonstrate new generation applications, the Indian Space Research Organisation (ISRO) said. It is the “heaviest” satellite built by ISRO, the space agency said. GSAT-11 is the next generation “high throughput” communication satellite configured around ISRO’s  I-6K Bus, and it...
Post a Comment
Read more